Lagarde Michel 4

What Happened

• Michel Lagarde, Executive Vice President & COO of Thermo Fisher Scientific, was credited with a grant/award of 2,231 performance-based restricted stock units (RSUs). The Form 4 records the acquisition on 2026-02-25 at an acquisition price of $0.00 (award).
• The award was originally granted February 19, 2025; the Compensation Committee certified achievement of the applicable performance criteria on February 25, 2026. The RSUs vest in three equal tranches on February 28, 2026, 2027 and 2028.

Key Details

• Transaction date: 2026-02-25; transaction type: Award/Grant (code A); per-share price shown: $0.00.
• Number of RSUs: 2,231 total (performance-based); vests in three equal tranches per award terms.
• Filing date: Form 4 filed 2026-02-27 (appears to be within the typical two-business-day Form 4 reporting window).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnote: award was granted 2/19/2025; performance certification occurred 2/25/2026, triggering the award to be scheduled to vest as noted.

Context

• These are performance-based RSUs, not open-market purchases or sales. They represent compensation that vests over time once performance targets are met and therefore do not by themselves indicate immediate buying or selling by the insider.
• When each tranche vests, shares may be delivered and subject to tax withholding or other plan terms; the filing does not report any immediate sale or tax-withholding disposition.